Payment overview · 2025
General Payments
$784.15
38 reported records · 14 companies
Healthcare provider profile · identity verified
John J Hart, MD
Allopathic & Osteopathic Physicians|Family Medicine · HESSTON, KS · NPI 1689636698
Verified facts
What the public records show
CMS Open Payments records show John J Hart, MD received $784.15 in general payments during 2025 across 38 reported records.
Lilly USA, LLC accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.46 | 19.4% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.59 | 18.1% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$96.19 | 12.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.46 | 10.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.06 | 8.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.00 | 7.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.68 | 4.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.60 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.50 | 3.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.10 | 3.0% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.57 | 2.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $20.85 | 2.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.33 | 2.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.76 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $784.15 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $108.26 | 7 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $96.19 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $93.61 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $78.46 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $78.46 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $78.46 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $72.08 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.51 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.46 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.68 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.91 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $29.26 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 76 |
| Potassium Chloride | Potassium Chloride | 280 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 61 |
| Gabapentin | Gabapentin | 252 | 41 |
| Furosemide | Furosemide | 205 | 43 |
| Prednisone | Prednisone | 200 | 108 |
| Donepezil Hcl | Donepezil Hcl | 192 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 177 | 45 |
| Tramadol Hcl | Tramadol Hcl | 154 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 150 | 39 |
| Losartan Potassium | Losartan Potassium | 144 | 44 |
| Lisinopril | Lisinopril | 143 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 39 |
| Eliquis | Apixaban | 124 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 110 | 20 |
| Warfarin Sodium | Warfarin Sodium | 109 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 28 |
| Buspirone Hcl | Buspirone Hcl | 105 | 15 |
| Omeprazole | Omeprazole | 105 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 105 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 96 | 28 |
| Ezetimibe | Ezetimibe | 92 | 22 |
| Montelukast Sodium | Montelukast Sodium | 90 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 12 |
| Metformin Hcl Er | Metformin Hcl | 87 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 17 |
| Pregabalin | Pregabalin | 82 | 19 |
| Allopurinol | Allopurinol | 81 | 23 |
| Sertraline Hcl | Sertraline Hcl | 79 | 15 |
| Metformin Hcl | Metformin Hcl | 77 | 20 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 15 |
| Trazodone Hcl | Trazodone Hcl | 73 | 20 |
| Fentanyl | Fentanyl | 69 | suppressed |
| Celecoxib | Celecoxib | 67 | 16 |
| Ozempic | Semaglutide | 66 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 64 | suppressed |
| Azithromycin | Azithromycin | 62 | 49 |
| Cefdinir | Cefdinir | 62 | 48 |
| Famotidine | Famotidine | 61 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 15 |
| Hydrocortisone | Hydrocortisone | 59 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | suppressed |
| Alprazolam | Alprazolam | 58 | 19 |
| Aripiprazole | Aripiprazole | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 14 |
| Digoxin | Digoxin | 52 | suppressed |
| Estradiol | Estradiol | 52 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 36 |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Fluconazole | Fluconazole | 44 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 11 |
| Topiramate | Topiramate | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 12 |
| Belsomra | Suvorexant | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 11 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 20 |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | 11 |
| Movantik | Naloxegol Oxalate | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | 11 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Nystop | Nystatin | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 21 |
| Nystatin | Nystatin | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $784.15 · 38 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AJOVY, BREZTRI, CAPLYTA, COMIRNATY, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INTELLIS ADAPTIVESTIM, JARDIANCE, KISUNLA, MOUNJARO, Omnipod, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, Senza, UBRELVY, VRAYLAR, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error